Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma

被引：0
|
作者：
Larrosa, Crstina
Simao Rafael, Margarida
Pablo Munoz, Juan
Gorostegui, Maite
Castaneda Heredia, Alicia
Garraus, Moira
Mora, Jaume
机构：
[1] Hosp St Joan de Deu, Barcelona, Spain
[2] Hosp St Joan de Deu, Pediat Canc Ctr Barcelona, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10037
引用
收藏
页数：1
相关论文
共 50 条
  • [1] IRINOTECAN AND TEMOZOLOMIDE ACTIVITY FOR RELAPSED/PROGRESSIVE NEUROBLASTOMA DURING NAXITAMAB IMMUNOTHERAPY
    Perez, Juan Pablo Munoz
    Gorostegui, Maite
    Rodriguez, Amalia Varo
    Heredia, Alicia Castaneda
    Garraus, Moira
    Santa-Maria, Vicente
    Rafael, Margarida Simao
    Mora, Jaume
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S223 - S224
  • [2] Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
    Munoz, Juan Pablo
    Larrosa, Cristina
    Chamorro, Saray
    Perez-Jaume, Sara
    Simao, Margarida
    Sanchez-Sierra, Nazaret
    Varo, Amalia
    Gorostegui, Maite
    Castaneda, Alicia
    Garraus, Moira
    Lopez-Miralles, Sandra
    Mora, Jaume
    CANCERS, 2023, 15 (19)
  • [3] DINUTUXIMAB BETA-BASED CHEMO-IMMUNOTHERAPY FOR RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA: PRELIMINARY RESULTS
    Olgun, Nur
    Cecen, Emre
    Ince, Dilek
    Kizmazoglu, Deniz
    Baysal, Birsen
    Onal, Ayse
    Ozdogan, Ozhan
    Guleryuz, Handan
    Cetingoz, Riza
    Demiral, Ayse
    Olguner, Mustafa
    Celik, Ahmet
    Kamer, Serra
    Ozer, Erdener
    Altun, Zekiye
    Aktas, Safiye
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S225 - S225
  • [4] Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Koep, Sharif
    During, Maria
    Kushner, Brian H.
    CANCER RESEARCH, 2024, 84 (17)
  • [5] Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
    Zhu, Jia
    Wang, Juan
    Sun, Feifei
    Zhen, Zijun
    Chen, Tingting
    Lu, Suying
    Huang, Junting
    Zhang, Yizhuo
    Sun, Xiaofei
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Chemo-immunotherapy with dinutuximab beta in patients with relapsed/ progressive high-risk neuroblastoma: does chemotherapy backbone matter?
    Raiser, Patricia
    Schleiermacher, Gudrun
    Gambart, Marion
    Dumont, Benoit
    Defachelles, Anne- Sophie
    Thebaud, Estelle
    Tandonnet, Julie
    Pasqualini, Claudia
    Proust, Stephanie
    Entz-Werle, Natacha
    Aerts, Isabelle
    Ndounga-Diakou, Lee A.
    Petit, Arnaud
    Puiseux, Chloe
    Khanfar, Camille
    Rouger, Jeremie
    Mansuy, Ludovic
    Benadiba, Joy
    Millot, Frederic
    Pluchart, Claire
    Laghouati, Salim
    Geoerger, Birgit
    Vassal, Gilles
    Valteau-Couanet, Dominique
    Berlanga, Pablo
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [7] Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory neuroblastoma.
    Zhu, Jia
    Zhen, Zijun
    Wang, Juan
    Chen, Tingting
    Lu, Suying
    Sun, Feifei
    Huang, Junting
    Que, Yi
    Zhang, Lian
    Zhang, Yizhuo
    Sun, Xiaofei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Assessment of Chemo-Immunotherapy Regimens in Patients with Refractory or Relapsed Neuroblastoma: A Systematic Review with Meta-Analysis of Critical Oncological Outcomes
    Olgun, Nur
    Arayici, Mehmet Emin
    Kizmazoglu, Deniz
    Cecen, Refik Emre
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (03)
  • [10] Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma.
    Fernandez, Karen S.
    Sabnis, Amit J.
    Titapiwatanakun, Ruetima
    Baker, Katherine
    Tcheng, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345